Loomis Sayles & Co. L P Has $24.55 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Loomis Sayles & Co. L P reduced its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 2.8% during the 4th quarter, Holdings Channel reports. The fund owned 290,111 shares of the company’s stock after selling 8,475 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Axsome Therapeutics were worth $24,547,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of AXSM. JPMorgan Chase & Co. raised its position in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after purchasing an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at $2,599,000. Intech Investment Management LLC raised its holdings in shares of Axsome Therapeutics by 46.5% in the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock valued at $1,356,000 after buying an additional 5,087 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Axsome Therapeutics during the 4th quarter worth about $14,771,000. Finally, PDT Partners LLC bought a new stake in Axsome Therapeutics during the 3rd quarter worth about $1,052,000. 81.49% of the stock is currently owned by institutional investors.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on AXSM shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research note on Monday, March 3rd. Leerink Partners upped their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, February 10th. Bank of America lifted their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Wells Fargo & Company boosted their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Finally, Robert W. Baird lifted their price objective on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.64.

Axsome Therapeutics Stock Down 2.7 %

Shares of NASDAQ AXSM opened at $118.53 on Friday. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The stock has a market cap of $5.78 billion, a P/E ratio of -19.79 and a beta of 1.00. The firm has a 50 day moving average price of $119.67 and a 200 day moving average price of $101.09.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.